Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Alamar Biosciences, Inc. is a commercial-stage proteomics company specializing in advanced protein detection and analysis technologies. It develops and commercializes the proprietary NULISA platform, designed to overcome limitations of traditional proteomics tools by enabling detection of protein biomarkers at extremely low concentrations in non-invasive biological fluids like blood. Key features include ultra-high sensitivity, high specificity, flexible multiplexing capabilities, broad dynamic range, and seamless automation, establishing a gold standard for precision proteomics. The company serves the healthcare sector, particularly the medical devices industry, by providing tools for disease detection research, including early identification of cancer and other diseases through protein biomarker platforms. Alamar Biosciences, Inc. focuses on powering precision medicine applications in research and diagnostics. Founded in 2018 and headquartered in Fremont, California, it plays a significant role in advancing proteomics for biological and clinical research.
$36.57
+$8.58 (+30.65%)
EOD Aug 11, 2026
The business is unprofitable at the operating level (-42.22% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 195.2% YoY with margins expanding 154.9pp.
Negative free cash flow of -$60M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$74M
▲ +195.2% YoY
Net Income (TTM)
-$30M
▲ +36.7% YoY
Op. Margin
-42.22%
▲ +154.9pp YoY
ROIC
-66.39%
▲ +51.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$60M
▼ -2.4% YoY
Op. Cash Flow (TTM)
-$54M
▲ +2.9% YoY
Net Debt
$11M
Cash & Equiv.
$30M
Continue Research
Alamar Biosciences (ALMR)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Alamar Biosciences scores 38/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Alamar Biosciences scores 38 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -42.2% operating margin and a -66.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ALMR's valuation and scores 38/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.